Juno Therapeutics, Inc. (JUNO): Hyam Levitsky , EVP, Research & CSO of Juno Therapeutics, Inc. sold 12,418 shares on Jun 17, 2016. The Insider selling transaction was reported by the company on Jun 21, 2016 to the Securities and Exchange Commission. The shares were sold at $42.98 per share for a total value of $531,080.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 13, 2016, Steve Harr (CFO & Head, Corp. Development) sold 30,000 shares at $43.29 per share price.On Jun 13, 2016, Hans Edgar Bishop (CEO & President) sold 90,750 shares at $47.38 per share price.Also, On May 20, 2016, Bernard J Cassidy (General Counsel & Secretary) sold 3,116 shares at $39.23 per share price.On May 20, 2016, Richard Klausner (director) sold 12,000 shares at $40.00 per share price.
Juno Therapeutics Inc: On Monday, Jun 20, 2016 heightened volatility was witnessed in Juno Therapeutics Inc which led to swings in the share price. The shares opened for trading at $43 and hit $44.42 on the upside , eventually ending the session at $43.36, with a gain of 2.26% or 0.96 points. The heightened volatility saw the trading volume jump to 10,37,316 shares. The 52-week high of the share price is $59.6 and the company has a market cap of $4,576 M . The 52-week low of the share price is at $22.37.
Company has been under the radar of several Street Analysts.Juno Therapeutics Inc is Initiated by Raymond James to Outperform and the brokerage firm has set the Price Target at $52. The Rating was issued on Jun 2, 2016.Juno Therapeutics Inc is Reiterated by Maxim Group to Buy and the brokerage firm has raised the Price Target to $ 80 from a previous price target of $78 .The Rating was issued on Apr 11, 2016.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.